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1. Introduction
The urinary system consists of two kidneys, two ureters, urinary bladder and urethra. The
main function of the urinary system is to eliminate wastes and harmful materials from the
body. Additionally, it adjusts blood volume and pressure, regulates electrolytes and blood pH.
The urine passes from the kidneys via the muscular tubes of ureters to the urinary bladder
where it is stored until it is socially convenient to be expelled outside through the urethra by
the act of micturition.
The urinary tract (ureters, bladder and urethra) is composed of two main functional tissues:
epithelial coverage (urothelium) and muscular coat (smooth muscle). A highly impermeable
urothelial layer is necessary to prevent reabsorption of noxious materials present in urine
despite its large osmotic and chemical gradients. Muscular coat creates coordinated waves of
contractions necessary for urine transport and expulsion.
Since birth, the urinary system is subjected to a variety of diseases and pathologies including
congenital and acquired disorders that threaten the patient`s life. Current therapeutic options
to replace severely damaged urinary organs are associated with many complications and
hazards on patient survival and quality of life. Regenerative medicine has emerged as potential
replacement treatment. Although progenitor cells of the urinary tract have been used in
experimental studies and clinical trials, however, they are not amenable options in cases of
benign end-stage diseases and malignancy. Stem cells can be the source of cellular components
in regenerating urinary organs. Among those stem cell types, Adipose-derived Stem Cells
(ASCs) are the current most convenient source due to easiness of harvest in abundant quantity,
potential differentiation into many cell types and lack of ethical problems.
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ASCs had also been investigated to form matrix (scaffold) and differentiate into urothelial and
smooth muscle cells. Both can be coupled together to form tissue-engineered constructs that
can replace the wall of urinary tract including ureters, urinary bladder and urethra. When
complete wall replacement is not needed in some situations, ASCs, as cellular therapy, had
beneficial benefits reflected on pattern of voiding. Additionally, ASCs can enhance vascularity
and improve survival of urinary flaps or grafts.
In this chapter, we will review the current and future applications of ASCs for regeneration
and repair of urinary tract. Mechanism of actions, preclinical and clinical trials and forms for
therapies will be addressed. We will highlight the challenges that face their use and potentials
to overcome these obstacles.
2. ASCs characteristics and prospectives for regenerative medicine
In the past, little consideration has been given to adipose tissue since its main functions were
mainly associated with the storage and release of lipids. For years, lipoaspirated material has
been discarded as surgical waste. Over the past few years, scientists became interested in
investigating this highly complex tissue. Adipose tissue is composed mainly of adipocyte cells
organized into lobules. The most prominent fraction, volume-wise, are mature adipocytes,
which store and hydrolyzed triglycerides in response to environmental signals. The stromal
vascular fraction (SVF), which includes preadipocytes, endothelial cells, vascular smooth
muscle cells, fibroblasts, resident monocytes/macrophages and lymphocytes [1] also, provides
structural support to adipose tissue. In 2002, a novel adult stem cell population isolated from
SVF was first identified by University of California,Los Angeles (UCLA) researchers and
named processed lipoaspirate (PLA) cells [2,3].
A wide variety of terms have been used to describe the multipotent cells derived from white
adipose tissues and there was no consensus on the nomenclature used, which can sometimes
lead to confusion. At the Second Annual International Fat Applied Technology Society (IFATS)
meeting in 2004, scientists concluded to refer to these cells as adipose-stem cells (ASCs) [53].
Accordingly, the term ASCs will be used throughout this chapter.
ASCs  are  mesenchymal  stem  cells  (MSCs)  and  possess  similar  characteristics  to  those
extracted from bone marrow or umbilical cord [4]. They are undifferentiated non-embryon‐
ic multipotent stem cells, which have the ability to divide and self-renew in undifferentiat‐
ed  state.  When  submitted  to  specific  inductive  signals,  ASCs  can  mature  into  a  broad
spectrum of cell lineages. ASCs have been reported to express the MSCs surface protein
markers  CD10,  CD13,  CD29,  CD44,  CD54,  CD73,  CD90 and CD105 (Table  1)  [5].  Major
differences occur for the CD34 stem cell marker that is not express by MSCs, but is present
in  ASCs in  early  passages.  Morphologically,  ASCs are  fibroblast-like  and preserve  their
shape after expansion in vitro [6].
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Cell surface markers Level of expression
CD3
CD10
Low or negative
High
CD11b Negative
CD14 Negative
CD29 High
CD34 Variable
CD44 High
CD45 Negative
CD73 High
CD90 High
CD105 High
HLA-DR Negative
Table 1. Expression level of ASCs surface markers
2.1. Isolation of ASCs from adipose tissue
When compared to other stem cell populations and sources, ASCs can be easily harvested
while providing higher yields upon processing of adipose tissue, with minimal discomfort
under local anaesthesia [7]. The efficiency of the cell isolation process depends on the locali‐
sation of the white adipose tissue and the donor general condition. For example, ASCs from
visceral deposits are more prone to apoptosis and, therefore, less proliferative than the same
cells isolated from the subcutaneous deposits [8]. ASCs are ususally isolated from subcutane‐
ous adipose tissue samples removed during liposuction, lipoplasty or lipectomy procedures,
which are minimally invasive or painful. Adipose tissue is one of the richest sources of MSCs.
From 1 gram of adipose tissue, 5 × 103 colony-forming stromal cells can be isolated, which is
500 times more cells than from an equivalent amount of bone marrow [9]. Current protocols
used for release the cells rely on enzymatic digestion with collagenase, dispase, trypsin or
related enzymes. Following the centrifugation and neutralization of the enzymes, the SVF
fraction sediment is separated from the floating mature adipocytes. When seeded in culture
flasks, the ASCs lack the intracellular lipid droplets seen in adipocytes and adhere to the plastic
surface where they can be purified from other SVF cells using a combination of washing steps
and culture expansion. Several exogenous supplements have been shown to have a stimulatory
effect on the proliferation of ASCs. Platelet-derived growth factor, sphingosylphosphorylcho‐
line, oncostatin M, and fibroblast growth factor (FGF) 2 have all been shown to increase ASC
proliferation [9, 10, 11, 12].
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2.2. ASCs potentials for regenerative medicine
The potential use of stem cell-based therapies for the repair and regeneration of various tissues
and organs offers alternative therapeutic solutions for a number of diseases. Developments in
stem cell research provided new cell source for regenerative medicine. An emerging body of
literature suggests that adipose tissue may provide an abundant, readily accessible source of
cells with similar potential to that described for other adult stem cells.
Adult stem cells are far more plastic than had previously been imagined. ASCs have been
described as being able to give rise to several quite different mesenchymal cell phenotypes
including osteocytes, adipocytes, neural cells, vascular endothelial cells, cardiomyocytes,
pancreatic β cells, and hepatocytes [13, 14, 15, 16].
Cell lineage Culture medium supplementation References
Adipocyte Insulin, dexamethasone, thiazolidinedione 17, 18
Chondrocyte Ascorbic acid, BMP-6, FGF, IGF, dexamethasone, TGF-β 19, 20
Osteoblast Ascorbic acid, BMP-2, valproic acid, dexamethasone 17
Myocyte Dexamethasone, horse serum 21
Cardiomyocyte Stem cell factor, transferrin, IL-3, IL-6, VEGF, TGF- β 22, 23
Neuronal-like Valproic acid, insulin, butylated hydroxyanisole,hydrocortisone 24
Hepatocyte-like HGF, FGF-1, FGF-4, oncostatin 24, 25
Table 2. Differentiation potential of ASCs
However, the ability to differentiate is not the only characteristic that makes these cells
attractive for therapeutic purposes. Some reports have suggested that the therapeutic effects
observed following ASCs administration, such as promotion of angiogenesis, reduction of
inflammation, and functional recovery, are largely related to the trophic actions of their
cytokines and growth factors secretion rather than by their differentiation into local tissue cell
types [26]. The secretion of a broad range of bioactive molecules by ASCs, such as growth
factors, cytokines and chemokines, constitutes their most biologically significant role under
injury conditions [27]. Analyses of the soluble factors released from human cultured ASCs
have revealed that, at relatively early passages, they secrete hepatocyte growth factor (HGF),
vascular endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), insulin-like
growth factor (IGF)-1, fibroblast growth factor (bFGF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), tumour necrosis factor (TNF)-α, interleukin (IL)-6, 7, 8, and 11,
adiponectin, angiotensin, cathepsin D, pentraxin, pregnancy zone protein, retinol-binding
protein, and CXCL12 [28, 29, 30]. These factors promote an anti-inflammatory environment,
angiogenesis and wound healing, which likely potentiate tissue repair.
ASCs possess immunomodulatory effects through their production of various soluble factors
and rather low immunogenicity properties. In vitro, they have the ability to inhibit maturation
of dendritic cells and suppress the proliferation of B cells, T cells, and natural killer cells
following activation through both cell to cell binding and paracrine signalling [31, 32]. During
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inflammation, ASCs release TGF-β that promotes premature helper T-cell differentiation
toward T regulatory cells promoting anti-inflammatory environment [33]. Moreover, ASCs
promote tryptophan degradation, limiting the bioavailability of a crucial molecule for T-cell
proliferation and function [34]. Low expression levels of class I Major Histocompatibilty
Complex (MHC-I) and lack of MHC-II and co-stimulatory molecules on the cell surface (CD80
and CD86] makes ASCs immunoprivileged cells [35].
During the past decade, several studies have provided preclinical data on the safety and
efficacy of ASCs administered in various animal models, supporting the use of these cells in
future clinical applications. Furthermore, various clinical trials have shown the regenerative
capability of ASCs in a variety of medical fields such as plastic surgery, autoimmune and
inflammatory disorders, orthopedic surgery, oral and maxillofacial surgery, cardiac surgery
and urology [36, 37, 38].
3. ASCs and kidney repair
Cell therapies using ASCs are highly promising in various clinical fields based on in vitro and
in vivo research results. Important experimental findings in recent years suggest considerable
therapeutic potential for cellular replacement in the context of kidney diseases (Figure 1).
3.1. Acute kidney injuries
Acute kidney injury (AKI), a multi-factorial syndrome that is common but often asymptomatic,
is caused by such incidents as major infections, trauma, complications following major surgery
and adverse reactions to drugs. It is characterised by the rapid loss of the kidney's functions,
usually occurring within 48 hours or less, and represents a major treatment-resistant clinical
problem with high mortality rates. In United States, AKI is an increasingly prevalent condition
in hospitalized patients, a 10 percent increase per year, and the number of associated deaths
has more than doubled over the last decade [39].
In the last few years, many studies have shown that stem cell transplantation is an efficient
method for AKI repair. It was shown that ASCs drastically reduced mortality and improved
renal structural and functional recovery using an animal ischemia-reperfusion model of AKI
[56]. Indeed, intrarenal arterial injection of ASCs in ischemia-reperfusion-induced AKI rat
model reduced blood urea nitrogen and creatinine levels [40]. Moreover, in a dose-dependent
manner, ASCs reduced the tubular injury score 48 hours after ischemia-reperfusion [40]. The
precise mechanism that attenuates kidney injury after ASCs injection remains to be clarified.
The renoprotective effects might be attributable to the replacement of damaged tubular cells
by transdifferentiation of ASCs. The injured kidney expresses renotypic factors that may
influence the differentiation of ASCs into a renal tubular epithelial lineage [41, 55]. A study
using a murine model of AKI showed that differentiation and replacement of the dead cells at
an early stage of injuriy by ASCs seems to be one of the major mechanisms in AKI kidney
repair. However, most studies indicate that intravenously injected ASCs show minimal
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homing to renal tubules and have limited survival in the kidney environment [42]. To bypass
this problem, scientists tried to inject ASCs directly at the injury site. However, more than 80%
of grafted cells die within the first week after injection and the majority of cells leak out from
the injection site. Recently, it was found that using an injectable scaffold could improve the
survival of cells as well as enhance retention of ASCs at the injury site [43].
There are increasing evidences that other differentiation-independent mechanisms of ASCs
play key role in promoting tissue repair. Beneficial effects could be partially explained by the
anti-inflammatory and anti-oxydative properties of ASCs, as revealed by their capacity to
reduce apoptosis and inflammation in the injured kidney tissue [56]. Indeed, the expression
of inflammatory, oxidative stress and apoptotic biomarkers such as IL-10, glutathione
peroxidase and TNF-α at both gene and protein levels, were significantly decreased in ASCs
treated group in ischemia-reperfusion rat model [45].
3.2. Chronic kidney disease
Twenty-six million american adults have chronic kidney disease (CKD) with progression of
the disease leading to kidney failure, which requires dialysis or a kidney transplant to maintain
life.
Positive effects of bone marrow MSCs treatment in CKD animal models have been reported
[46, 47]. However, bone marrow MSCs derived from CKD patients failed to provide the same
beneficial effect [48, 49]. A recent study has shown that ASCs did not seem affected by renal
disease [50]. Thus, the impact of ASC therapy has been studied in different CKD animal
models. In the majority of induced models investigated, ASCs administration has resulted in
beneficial therapeutic effects, as evidenced by decrease the speed of renal fibrosis progression
and improvement in renal functional parameters such as plasma creatinin, proteinuria and
renal filtration. Indeed, intraperitoneal injection of ASCs in ischemia-reperfusion CKD mouse
model reduced renal dysfunction and tubular injuries after 24 h post-reperfusion [44]. At 6
weeks, ASCs-treated animals showed reduced renal fibrosis [44].
The mechanisms mediating the therapeutic effects described are still under investigation.
ASCs would enhance the angiogenic process in CKD by increased expression of VEGF, a
growth factor that stimulates new blood vessels formation, suggesting a paracrine mechanism.
Moreover, the level of BMP-7 and Pax-2, two proteins that participate in cellular repair
response to kidney damage, increased after ASCs administration in CKD models [52].
3.3. Graft tolerance
Kidney transplantation remains the best therapeutic option for patients with end stage renal
disease. In 2012, the Scientific Registry for Transplant Recipients reported that approximately
17 000 kidney transplants were performed and over 92 800 patients were remaining on the
waitlist at the end of the survey year [54]. Unfortunately, transplanted patients need life-long
immunosuppressive drugs to prevent allograft rejection. This phenomenon may happen when
transplantation of a kidney from a donor who differs genetically from the graft recipient
induces an immune response in the recipient against alloantigens of the donor graft. Effector
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T cells infiltrate the graft and orchestrate an inflammatory response leading to destruction of
the tissue. The new immunosuppressive drugs have improved short-term patient survival but
rejection remains a major problem. Effective treatments are necessary to effectively address
the problem of transplanted organ rejection.
Because of their immunomodulatory properties, ASCs are believed to play a role in the
induction of transplantation tolerance. Studies have shown that ASCs attenuated acute
rejection in kidney transplantation by increasing graft survival and reducing rejection grade
[60]. A kidney transplantation study in rats that received intravenous injection of autologous
ASCs before intervention showed decreased infiltration of macrophages and lymphocytes into
the allograft and suppression of alloreactive T cells [60]. Studies reported that graft tolerance
can be induced by ASCs therapy. Indeed, donor-ASCs portal infusion in a 29 year-old recipient
before renal transplantation induced production of T-regs cells [59]. At 2-years post-transplant,
immunosuppression weaning was started and 6 months later, anti-rejection therapy was
completely stop with normal graft function. An Indian study in 90 patients showed similar
results [57]. Consequently, ASCs may serve as effective immunomodulators in clinical
transplantation. Long-term studies in larger populations are required to confirm efficacy.
Indication Disease model Cells used FunctionalAssessment Ramakes References
Acute renal injury
(AKI)
Ischemia-reperfusion
rat model Human ASCs
Urea and creatinine
level. Tubular injury
score.
Improved renal
recovery. 40
Ischemia-reperfusion
mouse model Human ASCs
Dead cells
replacement
Improved renal
recovery. 51
Ischemia-reperfusion
mouse model Mouse ASCs -
Improved renal
recovery. 58
Ischemia-reperfusion
rat model Rat ASCs
Inflammation,
oxidative stress and
apoptose
Reduce
inflammatory
and oxidative
stress reaction.
45
Chronic kidney
disease (CKD)
5/6 NPX rat Human ASCs
Creatinine level,
structural analysis,
angiogenesis
Improved renal
recovery. 52
Ischemia-reperfusion
mouse model Human ASCs
Renal fibrosis,
inflammation
Improved renal
recovery. 44
Graft Tolerance
Rat kidney
transplantation Rat ASCs
Inflammation,
rejection
Improved graft
tolerance 60
Human kidney
transplantation Human ASCs
Inflammation,
rejection
Improved graft
tolerance 57
Table 3. Shows the potential of ACSs as Kidney cellular therapy.
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Figure 1. ASCs reduce inflammation by direct (cell–cell contact) and indirect (paracrine) actions, by suppression of T-
cell and induction of Treg. The differentiation of ASCs into tubular epithelial cells can contribute to kidney recovery.
Microvascular damage is reduced by the secretion of the growth factor VEGF, which promotes angiogenesis.
4. ASCs and urinary tract
4.1. Urinary tract reconstruction
The urinary tract is anatomically composed of the renal pelvis, ureters, urinary bladder and
urethra. It is concerned with urine transport from the kidneys, storage and expulsion outside
of the body. Histologically, it is formed of 3 different layers including epithelium, connective
tissue forming the submucosal layer and smooth muscle on the outside. The epithelial coverage
is composed of transitional epithelium called urothelium, the function of which is to prevent
the reabsorption of noxious materials present in urine despite its large osmotic and chemical
gradients. Muscle layer creates coordinated waves of contractions necessary for urine transport
and expulsion. The submucosa is formed of extracellular matrix containing blood vessels,
lymphatics, nerves and variety of cells; predominantly fibroblasts.
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The urinary tract is the target of many congenital and acquired insults that affect certain or all
layers of the organ involved, resulting in partial or complete loss of function. This influences
the patient survival and quality of life.
Although the urinary tract is naturally equipped with progenitor cells in the urothelium and
muscle layers that help the regeneration of the urinary tract after any insult, severe disruption
of the involved layer or the whole structure may exceed the capacity of the local progenitors
or stem cells to compensate for the cellular loss. Hence, a necessity for repair with exogenous
therapies emerges to restore the structure and hence the function, partially or completely.
Replacing the damaged urinary organs with non-native tissues is related to many problems
including the lack of available tissues and postoperative complications including metabolic
derangements. Regenerative medicine has evolved as a potential solution for replacing the
damaged urinary tract. The patient’s own cells that can be used in regenerating urinary tract
are either local progenitors or stem cells. Local progenitor cells cannot be utilized in many
instances as cancer or end stage benign diseases being the reasons for the defect. Consequently,
stem cells should be harvested to build up new tissues for replacement.
Ideally, for clinical use, stem cells should be harvested in abundant quantities, by a minimally
invasive procedure, and differentiated along multiple cell lineage pathways in a reproducible
manner. Also, it can be manufactured in accordance with current Good Manufacturing Practice
guidelines [61]. For these reasons, ASCs represent an ideal source for stem cell therapy
especially for repairing the urinary system [62]. Additional advantages for the urogenital tract,
ASCs populations likely contains vascular stem cells at various stages of differentiation toward
becoming smooth muscle cells (SMCs) and endothelial cells (ECs), which are required
components for regenerating the urinary tract [63]. Furthermore, ASCs have the ability to
secrete many potentially synergistic proangiogenic growth factors delineating their angiogenic
and antiapoptotic potential.
4.2. ASCs Contribution to urinary tract reconstruction
ASCs can be the source for epithelial and muscle cells through many established protocols of
differentiation. Also, they can provide extracellular matrix (ECM) scaffold that sustains
mechanical stress and supports the formation of epithelial coverage.
4.2.1. ASCs as cell source
1. Undifferentiated mesenchymal stem cells:
Unmodified ASCs can be seeded on different scaffolds to replace the urinary tract. In vivo
differentiation of ASCs into SMCs has been observed after delivery of unmodified human
ASCs within the bladder wall of nude mice [64], or autologous rat ASCs seeded on scaffold
[65]. However, this phenotypic conversion occurs for a small percentage of the delivered ASCs.
2. Urothelial cell differentiation:
The main challenge in differentiating ASCs into urothelial cells (UCs) is due to the fact that
the urothelium is derived from the endoderm [66], but ASCs are derived from the mesoderm,
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making cross-blastoderm induction difficult. In vitro differentiation of ASCs into UCs was
achieved using either conditioned medium [67], growth factors as all-transretinoic acid [68] or
direct (seeding both cell types together) or indirect (using Transwell system { Corning-Costar})
coculture with UCs [69,70]. Lineage specific markers such as keratin 18 and uroplakins were
detected with high percentage among differentiated cells. ASCs were labeled with CM-DiI and
mixed with immortalized human bladder urothelial cells in a collagen matrix to be implanted
in subcutaneous tissue of athymic mice. After 4 weeks, the expression of uroplakin-Ia was 70%
and the expression of uroplakin-II was 65%. However, there was a lack of organized stratified
urothelium [70].
The difficulties of final phenotypic conversion of ASCs into UCs may be attributed to the lack
of epithelial-specific microenvironment including 3D biomimetic culture conditions, mesen‐
chymal component with its cross talk with UCs (organ-specific ECM and fibroblasts). Identi‐
fying the key factors responsible for induction of urothelial markers in previous experiments
is another difficulty [71].
3. Smooth muscle cell differentiation:
ASCs are easier to differentiate into smooth muscle cells. A subpopulation of adipose SVF was
isolated and proved to be different from other classes of adipose-derived cells after expanding
SVF cells with DMEM (Dulbecco's Modified Eagle Medium) plus 10% FBS (fetal bovine serum).
They were called adipose-derived SM-like cells as they consistently express SMCs markers
(Smooth muscle alpha actin, Smooth muscle myosin Heavy chain, Myocardin, SM22 and
calponin), independent of donor site and across multiple passages [72]. SMC differentiation
could be achieved either with chemical induction using different protocols [73, 74] or with
coculture with SMCs [64]. Mechanical extension stimulation could improve the feasibility of
ASCs induction into SMCs [75]. When mature SMCs are seeded on collagen scaffolds and
implanted in vivo, they not only regenerate SMCs needed for contraction but they also reduce
inflammation and promote neovascularization [76].
4.2.2. ASCs as a possible source of scaffolds
The use of acellular matrices or synthetic scaffolds can be associated with immunologic
reactions and possibility of infection transmission as exogenous ECM materials still retain a
significant portion of residual DNA. Therefore, a new method was developed; the self-
assembly method; to produce a tissue built by the cells themselves where a dense ECM is
completely produced by fibroblasts. In opposition to all exogenous scaffold models, these
models are autologous, which is a real advantage by eliminating the biocompatibility concerns.
The absence of immunological response should reduce the inflammatory and fibrotic reactions
and consequently improve the success rate of the procedure. Although this method has been
developed for skin engineering in case of severe burn, however, its use has been extended to
a wide variety of applications ranging from skin to blood vessels [77-79].
Our group has explored this unique technique for the reconstruction of urethra, urinary
bladder and tunica albuginea [80-86]. As ASCs were able to lay down collagen-based matrix
under the influence of ascorbic acid using the self-assembly technique [87], they would form
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another alternative for scaffolds for urinary tract regeneration. Additionally, they have been
shown to allow the growth and stratification of epithelial cells when seeded on top [88]. ASCs
have been utilized to form vesical equivalents and showed that there was no significant
structural difference between a ASCs and a dermal fibroblasts equivalents. When compared
to matrix synthesized from fibroblasts cultured under the same conditions, ASCs matrix was
thicker and showed comparable failure strain [89].
4.3. Reconstruction of urinary tract with ASCs
4.3.1. Tissue engineering of the ureter
Ureteral damage may result from trauma or pathologies that lead to stricture formation
obstructing the urine flow from the kidneys to the urinary bladder. The resulting ureteral
defects may be short or long. While bridging short defects is usually surgically feasible, the
reconstruction of long defects require extensive surgical repair that is not always possible and
may carry complications including metabolic derangements and tissue harvest problems.
Accordingly, new therapeutic options incorporating urothelium and avoiding ample tissue
harvest are required.
Tissue engineering can offer these new therapeutic options. Unlike urethra and bladder,
ureteral tissue engineering is only at its beginning. Unseeded synthetic or naturally derived
biomaterials were used in few animal studies and resulted in ureterohydronephrosis due to
the lack of normal tissue formation [90]. Cell seeded scaffolds present the ideal template for
tubular ureteral regeneration. The seeded cells should include urothelial cells to prevent early
contact of the scaffold with harmful urine and smooth muscle cells to regenerate the muscular
layer necessary for urine transport through the ureter. Whenever autologous urinary tract cells
are not available, ASCs can be the source of these cells. ASCs were differentiated into UCs
through indirect coculture protocol and seeded on tubular polylactic acid (PLA)/collagen
scaffolds [91]. Strong evidence of differentiation into urothelial lineage was detected with
CK-18 and UP2. When implanted subcutaneously in athymic mice, the differentiated cells in
the graft survived, stratified and exhibited urothelial markers. In another study, when ASCs
were differentiated into SMCs and seeded onto decellularized rabbit aortas, at 16 weeks after
implantation, radiography revealed patent ureter with no stricture associated with evidence
of stratified epithelium and organized muscle bundles similar to the native tissue [92].
4.3.1.1. Tissue engineering of the urinary bladder
Cell-seeded scaffolds with autologous urinary tract cells represent the current strategy for
tissue engineering of the urinary bladder [93]. Clinical trials using autologous urothelial and
smooth muscle cells along with exogenous biomaterials have been performed [94]. Although
organ specific cells would be an ideal cell source, however they are not available in many
situations as in bladder cancer or benign end-stage bladder [95]. Stem cells derived from many
tissues including bone marrow, muscle and adipose tissue are possible options to bridge the
defective cell source in these situations. ASCs are more encouraging due to their previously
mentioned advantages. ASCs can form ECM matrix and can be differentiated into urothelial
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cells and SMCs (Figure 2). Both the matrix and the differentiated cells can be used together or
separately to reconstruct the urinary bladder for in vivo implantation.
ASCs have been used for in vivo studies for urinary bladder replacement or augmentation
whether unmodified [96, 65] or after differentiating them into SMC [73]. Unmodified autolo‐
gous ASCs were seeded on acellular matrices (bladder acellular matrix in rabbits or prepucial
matrix in rats) and showed increase in smooth muscle content in the seeded group and
improved bladder functional evaluation when compared to non-seeded scaffolds. However,
ASCs were not labeled; therefore the origin of the regenerated muscle cells at the site of the
seeded matrices was not known whether it is differentiated ASCs or growth of local bladder
cells during normal healing process. In another study, ASCs were differentiated into SMCs
and seeded on synthetic scaffold PLGA and implanted in rats to replace 50% of the bladder.
Labeled SMC-differentiated ASCs persisted in vivo, became more organized with time and
led to better bladder compliance when compared to non-seeded scaffolds. However, in either
of the previous studies, the urothelial cell layer was lacking, exposing the scaffold to urine
irritation in the early healing period in case of large defects, which may promote fibrosis and
scarring of the graft highlighting the importance of the urothelial layer.
Figure 2. Shows the possible contributions of ASCs in tissue engineering of urinary bladder
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4.3.1.2. Tissue engineering of the urethra
Tissue engineering of urethra, using seeded or unseeded scaffolds has been used with success
in preclinical studies and clinical trials [93]. Among the available models, a biomaterial made
by the self-assembly technique was fabricated from dermal fibroblasts and seeded with
urothelial cells [85]. As preliminary formation of UC-seeded ASCs matrices for bladder
replacement was achieved [89], it is expected that the same approach in tubularized form can
be used for urethral regeneration.
ASCs have been employed to constitute urinary tract epithelium [97] and SMCs [75] in urethral
tissue engineering. In the first study, ASCs were differentiated into urothelial cells with DMEM
(supplemented with 2% FBS, all-trans retinoic acid, epidermal growth factor, hepatocyte
growth factor, keratinocyte growth factor, hydrocortisone) at the air liquid interface to promote
urothelial differentiation. Then, they were seeded on bladder acellular matrix to be implanted
in rabbits. The urethral continuity was maintained with large caliber and the labelled differ‐
entiated urothelial cells survived and formed a stratified epithelial layer. In the second study,
ASCs were induced chemically with 5-azacytidine (5-AZA) to differentiate into SMCs under
mechanical extension stimulation. The autologous induced cells together with oral mucosal
epithelium cells were seeded on PGA mesh to replace urethral defects in dogs. The mechanical
extension-stimulated engineered urethras were developed into more normal architectures
resembling nearby native urethra. Whether they are source of SMCs or UC, ASCs, with their
advantages, can contribute significantly in urethral tissue engineering
4.3.1.3. Tissue engineering of urinary conduit
Urinary diversion after cystectomy with gastrointestinal segments is the current treatment for
patients with bladder cancer or benign end-stage bladder diseases as bladder exstrophy or
neurogenic bladder due to spina bifida. It can be either continent or incontinent diversion
depending on the patient ability to control urine evacuation. Incontinent urinary diversion
with ileal conduit is common; however it still carries the complications of the use of gastroin‐
testinal segments. That is why a new approach for construction of tissue engineered urothe‐
lium-lined urinary conduit was developed.
A limited number of studies incorporated the use of adult cells from the urinary tract to
construct neourinary conduit (NUC) [98]. Nevertheless, autologous cells in these disease states
are not appropriate source for formation of NUC. Stem cells differentiated to mature urinary
tract cells may be a suitable alternative for the development of NUC. ASCs as a source of easily
obtained autologous stem cells can be an ideal option. A study led by TengionTM [99] used
tubular scaffolds made of PLGA seeded with adipose-derived SMCs in a porcine cystectomy
model. Implantation of these constructs led to the formation of patent tubular neo-organ that
was histologically comparable to native urinary bladder. They had well developed urothelial
and smooth muscle layers with minimal collagen deposition. As a result, Tengion has started
Phase I clinical trials of NUC constructs in human patients requiring urinary diversion. This
Phase I study “Incontinent Urinary Diversion Using an Autologous NeoUrinary Conduit”
(http://www.clinicaltrials.gov/ct2/show/NCT01087697) is currently recruiting patients using
autologous adipose-derived SMC with biodegradable biomaterial.
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4.3.1.4. Tissue engineering of sling materials for urinary incontinence and pelvic organ prolapse
Synthetic slings used in treatment of urinary incontinence (SUI) and pelvic organ prolapse
(POP) have serious complications such as tissue erosion [100]. Biodegradable biological
materials; whether xenografts or allografts; are more likely to undergo tissue remodeling and
less likely to cause erosion [101]. They are designed to provide a scaffold of acellular material
to facilitate autologous cell infiltration and subsequent replacement of the graft tissue with
regenerated functional host tissue. However, they have the drawbacks of poor integration into
the host and rapid degradation with early recurrence [102]. A new approach was developed
to use a cell-seeded bioabsorbable material to attain a long-term repair. Addition of autologous
cells will help the formation of new ECM, leading to long-term mechanical integrity while the
degradable nature of the scaffold should avoid a harmful chronic inflammatory response,
allowing integration, neovascularization, and remodeling.
In two in vitro studies, ASCs were seeded onto biodegradable materials and the mechanical
properties and cell attachment were observed. In the first one, human ASCs were seeded on
a collagen mesh from porcine dermis. An increase in the mechanical properties after cell
seeding was observed [103]. In the second study, the authors compared the use of human oral
fibroblasts (OF) and ASCs seeded on poly-L-lactic acid (PLA) scaffolds as candidate cell types
for the development of a pelvic floor tissue engineered repair material (TERM). They found
that both cells were well attached and proliferated on scaffolds. The addition of any of the two
cell types led to improvement in the mechanical properties compared to non-seeded scaffolds
in vitro. In addition, ASCs produced more total collagen and a denser homogenous ECM than
OF with unrestrained scaffolds. The authors concluded that OF and ASC both appeared to be
suitable cell types to combine with biodegradable scaffolds, in the development of a TERM for
the treatment of SUI and POP [104]. Morever, autologous ASCs have the other advantages of
modulating the inflammatory response and promoting a weaker foreign body reaction, which
could have a beneficial impact in patients treated with cellularized meshes. Also, ASCs
decrease the degradation rate of the collagen meshes and enhance angiogenesis. However, it
remains to examine the in vivo response to these cell seeded meshes in animal studies as well
as their degradation rate and changes in mechanical properties over time.
Preclinical studies for urinary reconstruction are included in table 4.
Involved organ/
disease
Nature of the study/
disease model Cells used
Functional
Assessment Notes References
Ureteral
replacement
Athymic mice
Human ASCs
differentiated into
urothelial cells
Not available
The grafts was
implanted
subcutaneously for 14
days
91
Normal rabbits
Autologous rabbit
ASCs differentiated
into smooth muscle
cells
Intravenous
Urography (IVU)
IVU demonstrated no
ureteral stricture or
hydroureteronephrosis
.
92
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Involved organ/
disease
Nature of the study/
disease model Cells used
Functional
Assessment Notes References
Bladder
replacement
In vitro study Human culturedunmodified ASCs Not available
ASCs formed matrix
graft with good
mechanical properities
89
Normal rabbits
Autologous
cultured ASCs were
seeded on bladder
acellular matrix.
Cystography.
Normal bladder
capacity was
acquired.
Exogenous scaffold
was used. 96
Normal Rats
Autologous rat
ASCs were seeded
on decelluarized
prepuce
dynamically
Cystometry. It
showed better
parameters with
seeded group.
ASCs were not labeled.
Small number of
animals were used.
65
Athymic rats
Human ASCs
differentiated into
SMCs were seeded
on PLGA
Cystometry. It
showed better
compliance with
ASCs-SMC
seeded group.
Labeled ASCs
survived and formed
organized muscle
tissue.
73
Urethral
replacement
Normal rabbits
Autologous
cultured ASCs and
urothelial -
differentiated ASCs
were seeded on
bladder acellular
matrix.
Urethrography. It
revealed
restoration of
urethral
continuity with
only urothelial-
differentiated cell
seeded constructs
BrdU-labeled cells
survived in vivo
transplantation.
97
Normal canine
model
Autologous SMC-
differentiated ASCs
and oral epithelial
cells were seeded
on PGA scaffolds
Urethrography. It
showed slight
strictures at the
site of
implantation
The use of bioreactor
improved the
characters and
outcome of engineered
graft
75
Urinary conduit porcine cystectomymodel
Autologous
Adipose-derived
SMCs were seeded
on PLGA scaffolds
Not available
Urothelial and smooth
muscle regeneration
with no fibrosis
99
Pelvic sling
material
In vitro study
Human unmodified
ASCs seeded on
porcine dermis
Not available
Increase in mechanical
properties after cell
seeding
103
In vitro study Human oralfibroblasts and Not available
Both cell types had
good results regarding 104
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Involved organ/
disease
Nature of the study/
disease model Cells used
Functional
Assessment Notes References
unmodified ASCs
were seeded on
PLA scaffolds
cell attachment and
mechanical properties
Table 4. Shows the different studies involving the use of ASCs in urinary tract reconstruction.
5. Cellular therapy
5.1. Voiding dysfunction
There are approximately 400 million patients with bladder diseases, and a lot of them might
eventually need bladder reconstruction [66]. The International Continence Society and
International Urogynaecological Association define voiding dysfunction as abnormally slow
and/or incomplete micturition (voiding) based on symptoms and urodynamic investigations
[105]. Voiding dysfunction usually presents in 2 forms; lower urinary tract symptoms (LUTS)
and urinary tract decomposition [106]. Both affect the patient’s quality of life and survival. It
can be classified functionally into failure to store or failure to empty urine or both; and
anatomically, bladder dysfunction and bladder outlet dysfunction or both [107]. Bladder outlet
obstruction (BOO) causes voiding dysfunction through increased collagen deposition,
detrimental changes in ultrastructure of bladder SMCs and decrease blood flow [108]. All lead
to impaired smooth muscle function and decreased bladder compliance. The inadequate
efficacy of current pharmacological treatment and invasiveness of other modalities has
supported the search for new stable therapeutic modalities for voiding dysfunction including
bladder overactivity or underactivity. Additionally, none of the current treatments are able to
modify the pathologic effects in the diseased bladders.
Possible mechanisms for a role of ASCs for the treatment of voiding dysfunction
1. Engraftment:
When delivered either locally or systemically, ASCs are recruited to the affected tissue with
the effect being more pronounced with the local delivery. Homing cytokines, such as stromal
derived factor-1, has been shown to attract ASCs to the site of injury [109]. After an acute injury,
however, homing of transplanted stem cells may not be achieved because of the minimal
amount of tissue damage, which subsequently leads to less cytokine expression [110].
2. Differentiation
Few studies have shown in vivo differentiation of ASCs after transplantation [64, 65]. SMC
differentiation may occur due to the plasticity of ASCs and the effect of local bladder micro‐
environment rather than cell fusion [64]. The low evidence of in vivo SMC differentiation can
be explained by the fact that labelled DNA in dividing cells is quickly diluted by cell divisions
whereas dilution takes much more time for slow dividing stem cells [111] and the rapid wash
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of the cells from the desired sites into circulation with lack of time needed for phenotype
change. That is why in vitro differentiation of ASCs before delivery may be needed if SMC
regeneration in vivo is strongly required.
3. Paracrine effect
Growing evidence has been shown that the beneficial effects of ASCs are largely due to
paracrine actions with the release of cytokines and growth factors by the transplanted cells or
neighbouring cells [112]. These cytokines and growth factors result in anti-inflammatory,
musculotropic, angiogenic, antifibrotic and antiapoptotic actions. These actions cause modu‐
lation of local and systemic inflammatory responses and mobilization, stimulation and
differentiation of local stem cells, promotion of vascularisation of regenerating tissues and
reduction of fibrosis [113]. The secretome of ASCs includes: hepatocyte growth factor (HGF),
insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF) and basic
fibroblast growth factor (bFGF) [114]. In a rat model of BOO, human ASCs increased sequence-
specific transcription of Oct4, Sox2, and Stella in the submucosal and muscle layer of the rat
bladders. These are markers for primitive pluripotent stem cells. In addition, ASCs enhanced
the expression of several genes responsible for stem cell trafficking, including SDF-1/CXCR4,
HGF/cMet, PDGF/PDGFR, and VEGF/VEGFR signaling axis. Through these paracrine effects,
ASCs caused the stimulation and mobilization of endogenous stem cells [115].
5.2. Preclinical studies
ASCs could potentially reverse many of the bladder pathologic changes in different animal
models [113]. ASCs alleviated the symptoms of bladder dysfunction in various animal models
of detrusor overactivity [115, 116] or underactivity [117] or variable spectrum of voiding
dysfunction [112]. Also, ASCs seemed to preserve the bladder vascularity and decrease
apoptosis. Human ASCs decreased the frequency and irregularity of detrusor contractions and
slightly increased their amplitude when injected into the rat bladders subjected to outlet
obstruction [112]. This suggests the possibility of allogenic stem cells transfer for people with
perturbed stem cell depot as in diabetic or geriatric populations. There is no known human
trial incorporating the use of ASCs for treatment of voiding dysfunction.
ASCs  differentiated  into  SMC  before  local  injection;  have  been  shown  to  survive  and
increase SMC content at the injury site. However, no record on the improvement of bladder
function  after  injection  was  reported  [118].  Although  systemic  injection  of  ASCs  has
improved voiding dysfunction in animals, as seen with local injection into urinary bladder,
like  other  MSCs,  it  may  have  serious  side  effects  such  as  hemodynamic  compromise,
respiratory distress and impeding of pulmonary gas exchange that hinder its adoption as
a regular route of delivery [119].
It is important to note that ASCs can be useful in early stages of voiding dysfunction before
severe affection of the bladder wall happens. This beneficial effect may be preventive (arrest
of further pathologic effects) or ameliorative (correct existing pathologic effects) or both. The
exact underlying mechanisms, the magnitude and type of positive outcomes and durability
need to be furtherly investigated.
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5.3. Urinary incontinence
There are 17 million people in the USA and more than 200 million people worldwide who live
with urinary incontinence [120, 121]. Stress urinary incontinence (SUI) is the most common
type of urinary incontinence. SUI is involuntary leakage of urine with sudden increase in the
intra-abdominal pressure. It happens when intra-abdominal pressure causes the bladder
pressure to exceed the urethral closure pressure. SUI is classified into three conditions,
including intrinsic sphincter deficiency (ISD), urethral hypermobility, or a combination of both
[122]. Most of the patients have both disorders in varying degrees [123]. SUI affects both males
and females and decreases quality of life [124]. Many injectable bulking agents are minimally
invasive but have a poor long-term efficacy and complications such as chronic inflammatory
reactions, particle migration, periurethral abscess and erosion [125]. More invasive ap‐
proaches, like sling procedures, bladder neck suspensions or artificial urinary sphincter
implantation are more effective but have higher morbidity [126, 127]. More importantly, none
of these therapies replace the deficient urethral sphincter. The ideal strategy for treating SUI
using stem cell therapy besides being a bulking agent would be to allow for the regeneration
of functional periurethral tissues, provide adequate mucosal coaptation and restore or improve
resting urethral closure pressures [128].
5.4. Cell source for injection therapy
The ideal cells for cell therapy should be easily procured from minimally invasive procedures,
proliferate quickly in a well-controlled manner, provide sufficient quantities of cells, exhibit
capabilities of differentiation to regenerate multiple tissues, and be able to be transplanted into
an autologous host [129]. Currently, bone marrow-derived stem cells (BMSCs), adipose-
derived stem cells (ASCs), and muscle-derived stem cells (MDSCs) are the stem cell sources
applied in SUI therapy. ASCs carry future special importance in this regard due to its reported
myoblast and neuronal-like differentiation capacity and neovascularization potential in
addition to their ease of harvest and high stem cell content [130].
5.5. Preclinical studies and clinical trials
ASCs were used in many animal studies as SVF or cultured ASCs or differentiated into
myoblasts or coupled with biomaterials or with growth factors. Unmodified ASCs were
labelled and injected periurethrally and systemically into female rats after induction of SUI
postpartum vaginal balloon dilation and bilateral ovariectomy. There was improvement in
cystometric parameters in 2/3 of the rats treated locally or systemically in relation to control
animals with increase in muscle and elastin content. The ASCs beneficial effects were attributed
mainly to growth factors that supported host tissue regeneration as most of the delivered ACSs
remained undifferentiated after injection [131]. ASCs were also used in another model of SUI
after injury to pudendal nerve injury. ASCs were labelled and injected at 3, 9, and 12 o’clock
around the mid and distal urethra. Urodynamic evaluations revealed considerable improve‐
ments in maximum bladder capacity, abdominal leak point pressure, maximum urethral
closure pressure and functional urethral length. Morphologic changes and significant im‐
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provement in urination control were consistent over time. Labeled cells gradually migrated in
vivo toward the urethra and its lumen from urethra’s edges [132].
ASCs were differentiated into myoblasts using 5-AZA and injected in the posterior urethra
after induction of SUI in rats. Maximal bladder capacity and abdominal leak point pressure
(ALLP) significantly increased 1 and 3 months after implantation with unmodified and
differentiated rat ASCs with better results in case of differentiated ASCs [133].
ASCs coupled with biodegradable microbeads as carriers improved in abdominal leak point
pressure (ALPP) and retrograde urethral perfusion pressures (RUPP) in a rat model of SUI
[134]. ASCs in combination with nerve growth factor (NGF) and PLGA resulted in significant
improvements in ALPP and RUPP as well as the amount of muscle and ganglia when com‐
pared to ASCs alone [135].
Few clinical trials are incorporating the use of ASCs for treatment of SUI (www.clinicaltri‐
als.gov). In a clinical trial, 11 male patients with persistent post-prostatectomy SUI received
ASCs in 2 fractions; ASCs alone and mixed with fat. SUI improved progressively in eight
patients during the 1-year follow up, as determined by a 59.8% decrease in the leakage volume
in the 24h pad test, decreased frequency and amount of incontinence, and improved quality
of life. One patient achieved total continence up to 12 months after stem cell injection [136].
In a pilot study, 5 female patients with SUI were included to be treated with ASCs combined
with bovine collagen gel and saline. The ASCs mixture with collagen was injected endoscop‐
ically through the urethra. The effect of the treatment was assessed objectively with cough test
as a primary end point and subjectively with validated questionnaire. At 1 year, the cough test
was negative for three patients; two of them were satisfied with the treatment and did not wish
further treatment for SUI. Validated questionnaires showed some subjective improvement in
all five patients [137].
Preclinical studies and clinical trials for cellular therapy are included in table 5.
Involved
disease
Nature of the study/
disease model Cells used
Functional
Assessment Notes References
Voiding
dysfunction BOO
Cultured Human
ASCs injected into
rat bladder wall
UDS. Decrease
bladder overactivity
(frequency and
irregularity of
contractions ) with
increase in bladder
voiding pressure.
115
Autologous
cultured ASCs
and muscle
precursor cells
UDS. Micturiting
pressure (maximum
and threshold) and
117
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Involved
disease
Nature of the study/
disease model Cells used
Functional
Assessment Notes References
(MPCs) injected
into rat bladder.
voided volumes
increased.
Diabetes Mellitus
Autologous
cultured ASCs
injected in
bladder wall or
tail vein of
diabetic type II
rats.
UDS. It showed
Diabetic Voiding
dysfunction
improvement in
40-60 %.
Improvement
with local
(bladder)
injection is
more effective
than systemic
(tail vein)
injection
112
Hyperlipidemia
Autologous
cultured ASCs
injected into
bladder or tail
vein of
hyperlipdemic rat
Improved
micturition
frequency and
voided volumes
Improvement
with direct
(bladder)
injection is
more efficient
than systemic
(tail vein)
injection
117
Cryo-injury
Human ASCs
differentiated into
SMCs and
injected into cryo-
injured bladder
wall of mice.
Not available
There was an
Increase in the
ASMA
positive area
of injured
Bladder. The
injected
labeled cells
were detected
in vivo.
118
Urinary
incontinence
Stress urinary
incontinence (SUI) -rat
model
Autologous
unmodified ASCs UDS with different
measures including
ALPP, RUPR and
bladder capacity
SUI was
induced by
vaginal
balloon
dilation and
bilateral
131
Ovariectomy.
Unmodified ASCs
and ASCs
differentiated
into myoblasts
133
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Involved
disease
Nature of the study/
disease model Cells used
Functional
Assessment Notes References
Autologous
unmodified ASCs
SUI was
induced by
pudendal
nerve injury.
135
Cultured ASCs
with PLGA
microbeads
SUI was
induced by
urethrolysis.
134
Autologous
cultured ASCs
with PLGA or
NGF or both
SUI was
induced by
bilateral
pudendal
nerve
transection
135
Postprostatectomy
urinary incontinence –
clinical trial
11 patients
received
autologous ASCs
with and without
fat.
Frequency and
amount of
incontinence, daily
leakage volume,
UDS and ICIQ-SF
The cells were
injected
endoscopicall
y into the
region of
external
urethral
sphincter and
submuocal
space.
136
Female SUI-clinical trial
5 female patients
received ASCs
combined with
bovine collagen
gel and saline
Cough test and
questionnaire
The mixture
was injected
transurethrall
y via
cystoscope
137
BOO=bladder outlet obstruction SMC=smooth muscle cells / ASMA=smooth muscle α-actin /PGA=Poly-Glycolic acid
PLGA=poly(lactic-co-glycolic acid) /NGF=Nerve growth factor
ICIQ-SF=The International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)
UDS=Urodynamic study
ALPP=abdominal leak point pressure
RUPP=retrograde urethral perfusion pressure
Table 5. Shows the different animal studies and human trials with ASCs as a cellular therapy for lower urinary tract.
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6. Hurdles and future directions
There are many hurdles that face the broad utilization of ASCs in clinical therapies for urinary
tract diseases. First of all, is the limited ASCs efficiency for the treatment of chronic diseases.
This can be explained by the fact that in chronic pathologies, there are less release of cytokines
and so minimal attraction of ASCs to the site of the disease [138]. Research is needed to improve
the accuracy of predictions regarding disease progression. Similarly, the time delay between
injury and the initiation of treatment represents an obstacle as after an acute injury, homing
signals are often diminished with time. Therefore, it is important to determine the duration of
time after injury that equates to the optimal release of homing bioactive factors and to develop
innovative methods for up-regulating the expression of these cytokines. Methods such as
electrical stimulation or local injection of homing cytokines could help the direct recruitment
of systemically delivered stem cells to the target organ [139].
The second is the form of delivery of ASCs; whether differentiated or undifferentiated cells
would allow better regeneration of the urinary tract. It would be interesting to investigate
whether pre-differentiation of ASCs into the targeted tissue cell types would increase their
benefits and help engraftment without affecting their secretomes. A mix of differentiated and
undifferentiated cells may be a good option.
Moreover, there is no final agreement on the preferred type of cells to use (SVF cells or cultured
ASCs), total number of cells for the treatment or the number of cells for single injection.
Although recent studies showed that after cell labelling, ASCs migrate into the bone marrow
after systemic or local delivery [140,109,141], however, more precise imaging studies are
required to to observe the fate of the implanted ASCs regarding cell survival, proliferation,
migration and formation of functional tissues [142]. Live image tracing might be a good choice
for that purpose [143]. Neovascularization and reinnervation of engineered tissues are critical
obstacles to overcome for future application to bladder reconstruction. Ingrowth of native
vessels and nerves—which is stimulated by MSCs bioactive factors—is achievable for smaller
grafts; however, complete regeneration with functional integration is far more challenging.
ASCs are able to secret some cytokines, which can modulate the host inflammatory response,
and guards against severe inflammatory and fibrotic responses damage in the urinary tract
[144]. The contributions of each of the cytokines and growth factors to the repair of urinary
tract need to be evaluated. Finally, the safety of ASCs-based treatment needs to be carefully
checked as ASCs have the potential risk of tumorigenic transformation [145]. Hence, more
chronic animal models, consistent protocols and many clinical trials are required to make sure
of ASCs therapeutic efficacy and safety.
7. Conclusions
Tissue Engineering and Regenerative Medicine is an emerging field of research for organ and
tissue replacement to compensate for the deficiency of organ donation and complications of
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immunosuppression. In the search of new therapeutic options for urinary tract disorders, both
SVF and cultured ASCs have been the focus of numerous in vitro studies, various animal
models and few clinical trials. Depending on the type of dysfunction to be treated, ASCs can
be used either as cellular therapies or combined with scaffolds for tissue-engineering appli‐
cations. Although few clinical trials showed promising results, however, more future clinical
studies are required to prove their efficacy for those particular applications while exploring
the mechanisms ensuring their functional activity. Clinical trials are listed for the use of ASCs
in different diseases including urinary incontinence, renal failure, ischemic nephropathy and
urethral strictures in males (http://www.clinicaltrials.gov/).
Acknowledgements
We acknowledge the Canadian Institutes of Health Research (grant #79437), Canadian Male
Sexual Health Council (CMSHC), Fonds de la Recherche du Québec en santé (FRQ-S).
Author details
Hazem Orabi, Cassandra R. Goulet, Julie Fradette and Stéphane Bolduc*
*Address all correspondence to: stephane.bolduc@fmed.ulaval.ca
Centre de recherche en organogénèse expérimentale de l’Université Laval / LOEX, Division
of Regenerative Medicine, CHU de Québec Research Centre. Québec City, Canada
References
[1] Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, Johnstone
BH, March KL. A population of multipotent CD34-positive adipose stromal cells
share pericyte and mesenchymal surface markers, reside in a periendothelial loca‐
tion, and stabilize endothelial networks. Circ Res 102(1):77-85, 2008.
[2] Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser
JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem
cells. Mol Biol Cell 13(12):4279-4295, 2002.
[3] Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP,
Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-
based therapies. Tissue Eng 7(2):211-228, 2001.
[4] Witkowska-Zimny M, Walenko K. Stem cells from adipose tissue. Cell Mol Biol Lett
16(2): 236-257, 2011.
Adipose-Derived Stem Cells — Are They the Optimal Cell Source for Urinary Tract Regeneration?
http://dx.doi.org/10.5772/59223
25
[5] Romanov YA, Darevskaya AN, Merzlikina NV, Buravkova LB. Mesenchymal stem
cells from human bone marrow and adipose tissue: isolation, characterization, and
differentiation potentialities. Bull Exp Biol Med 140(1):138-143, 2005.
[6] Zannettino AC, Paton S, Arthur A, Khor F, Itescu S, Gimble JM, Gronthos S. Multipo‐
tential human adipose-derived stromal stem cells exhibit a perivascular phenotype in
vitro and in vivo. J Cell Physiol 214(2):413-421, 2008.
[7] Casteilla, L. & Dani, C. Adipose tissue-derived cells: from physiology to regenerative
medicine. Diabetes Metab. 32, 393–401, 2006.
[8] Cawthorn WP, Scheller EL, MacDougald OA, Adipose tissue stem cells meet preadi‐
pocyte commitment: going back to the future, J Lipid Res, 53(2):227–246, 2012.
[9] Fraser J K, Wulur I, Alfonso Z, Hedrick M H. Fat tissue: an underappreciated source
of stem cells for biotechnology. Trends Biotechnol. 24 150-154, 2006
[10] Choi Y S, Cha S M, Lee Y Y, Kwon S W, Park C J, Kim M. Adipogenic differentiation
of adipose tissue derived adult stem cells in nude mouse. Biochem Biophys Res Com‐
mun. 345 631-637, 2006.
[11] Jeon E S, Moon H J, Lee M J et al.. Sphingosylphosphorylcholine induces differentia‐
tion of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-
beta-dependent mechanism. J Cell Sci 119 (Pt 23) 4994-5005, 2006.
[12] Eto H, Suga H, Matsumoto D et al.. Characterization of structure and cellular compo‐
nents of aspirated and excised adipose tissue. Plast Reconstr Surg. 124 1087-1097,
2009.
[13] Planat-Benard, V., Menard, C., Andre, M., Puceat, M., Perez, A., Garcia-Verdugo, J.
M., Penicaud, L. & Casteilla, L. Spontaneous cardiomyocyte differentiation from adi‐
pose tis-sue stroma cells. Circ. Res. 94, 223–229, 2004.
[14] Awad, H. A., Wickhan, M. Q., Leddy, H. A. Gimble, J. M. & Guilak, F. Chondrogenic
differentiation of adipose-derived adult stem cells in agarose, alginate, and gelatin
scaffolds. Biomaterials 25, 3211–3222, 2004.
[15] Okura, H., Komoda, H., Fumimoto, Y., Lee, C. M., Nishida, T., Sawa, Y. & Matsuya‐
ma, A. Transdifferentiation of human adipose tissue-derived stromal cells into insu‐
lin-producing clusters. J. Artif. Organs 12, 123–130, 2009.
[16] Konno, M., Hamazaki, T. S., Fukuda, S., Tokuhara, M., Uchiyama, H., Okazawa, H.,
Okochi, H. & Asashima, M. Efficiently differentiating vascular endothelial cells from
adipose tissue-derived mesenchymal stem cells in serum-free culture. Biochem. Bio‐
phys. Res. Commun. 400, 461–465, 2010.
[17] Neupane M, Chang CC, Kiupel M, et al. Isolation and characterization of canine adi‐
pose-derived mesenchymal stem cells. Tissue Eng Part A 14(6): 1007-15, 2008.
Cells and Biomaterials in Regenerative Medicine26
[18] Senesi S, Marcolongo P, Manini I, et al. Constant expression of hexose-6-phosphate
dehydrogenase during differentiation of human adipose-derived mesenchymal stem
cells. J Mol Endocrinol 41(3): 125-33, 2008.
[19] Pilgaard L, Lund P, Duroux M, et al. Transcriptional signature of human adipose tis‐
sue-derived stem cells (hASCs) preconditioned for chondrogenesis in hypoxic condi‐
tions. Exp Cell Res 315(11): 1937-52, 2009.
[20] Ogawa R, Mizuno S, Murphy GF, et al. The Effect of hydrostatic pressure on 3-D
chondroinduction of human adipose-derived stem cells. Tissue Eng Part A 15(10):
2937-45, 2009.
[21] Mizuno H, Zuk PA, Zhu M, et al. Myogenic differentiation by human processed lip‐
oaspirate cells. Plast Reconstr Surg 109(1): 199-209; discussion 210-1, 2002.
[22] Gwak SJ, Bhang SH, Yang HS, et al. In vitro cardiomyogenic differentiation of di‐
pose-derived stromal cells using transforming growth factor-beta1. Cell Biochem
Funct 27(3): 148-54, 2009.
[23] Van Dijk A, Niessen HW, Zandieh Doulabi B, et al. Differentiation of human adi‐
pose-derived stem cells towards cardiomyocytes is facilitated by laminin. Cell Tissue
Res 334(3): 457-67, 2008.
[24] Banas A, Teratani T, Yamamoto Y, et al. Adipose tissue-derived mesenchymal stem
cells as a source of human hepatocytes[J]. Hepatology 46(1): 219-28, 2007.
[25] Sgodda M, Aurich H, Kleist S, et al. Hepatocyte differentiation of mesenchymal stem
cells from rat peritoneal adipose tissue in vitro and in vivo. Exp Cell Res 313(13):
2875-86, 2007.
[26] Van Poll D, Parekkadan B, Borel Rinkes I et al. Mesenchymal stem cell therapy for
protection and repair of injured vital organs. Cell Mol Bioeng 1:42–50, 2008.
[27] Luis Fernando Arenas da Silva, Lionel Micol, Dorien Tiemessen, Toin H. van Kuppe‐
velt, Peter Frey, Egbert Oosterwijk, Paul Geutjes, and Wout F. Feitz. Is There a Need
for Smooth Muscle Cell Transplantation in Urethral Reconstruction? TISSUE ENGI‐
NEERING: Part A Volume 20, Numbers 9 and 10, 2014.
[28] Rehman J, Traktuev D, Li J et al. Secretion of angiogenic and antiapoptotic factors by
human adipose stromal cells. Circulation 109:1292–1298, 2004
[29] Salgado AJ, Reis RL, Sousa NJ et al. Adipose tissue derived stem cells secretome:
Soluble factors and their roles in regenerative medicine. Curr Stem Cell Res Ther
5:103–110, 2010.
[30] Kilroy GE, Foster SJ, Wu X et al. Cytokine profile of human adipose-derived stem
cells: Expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell
Physiol 212:702–709, 2007.
Adipose-Derived Stem Cells — Are They the Optimal Cell Source for Urinary Tract Regeneration?
http://dx.doi.org/10.5772/59223
27
[31] McTaggart SJ, Atkinson K. Mesenchymal stem cells: Immunobiology and therapeutic
potential in kidney disease. Nephrology (Carlton) 12:44–52, 2007.
[32] McIntosh. K.R. Evaluation of cellular and humoral immune responses to allogeneic
adipose-derived stem/stromal cells. Methods Mol Biol, 702;133–150, 2011.
[33] Li, M.O., Flavell. R.A. Contextual regulation of inflammation: a duet by transforming
growth factor-x and interleukin-10. Immunity, 28;468–476, 2008.
[34] Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses
by indoleamine 2,3-dioxygenase–mediated tryptophan degradation. Blood 103, 4619–
4621, 2004.
[35] Uccelli, A., et al. Immunoregulatory function of mesenchymal stem cells. Eur. J. Im‐
munol., 36;2566–2573, 2006.
[36] Fang, B. Song, Y. Liao, L. Zhang, Y. Zhao. R.C. Favorable response to human adipose
tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host
disease. Transplant Proc, 39; 3358–3362, 2007.
[37] Gonzalez MA, Gonzalez-Rey E, Rico L et al. Treatment of experimental arthritis by
inducing immune tolerance with human adipose-derived mesenchymal stem cells.
Arthritis Rheum 60:1006–1019, 2009.
[38] Mesimäki, K. Lindroos, B. Törnwall, J. et al. Novel maxillary reconstruction with ec‐
topic bone formation by GMP adipose stem cells. Int J Oral Maxillofac Surg, 38; 201–
209, 2009.
[39] Hsu, R. K. McCulloch, C. E. Dudley, R. A. Lo, L. J. Hsu, C.-Y. Temporal Changes in
Incidence of Dialysis-Requiring AKI. Journal of the American Society of Nephrology,
24, 37-42, 2012.
[40] Shih YC, Lee PY, Cheng H, Tsai CH, Ma H, et al. Adipose-derived stem cells exhibit
antioxidative and antiapoptotic properties to rescue ischemic acute kidney injury in
rats. Plast Reconstr Surg 132: 940e–951e, 2012.
[41] Morigi M, Imberti B, Zoja C et al. Mesenchymal stem cells are renotropic, helping to
repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 15:
1794–1804, 2004.
[42] Burst VR, Gillis M, Putsch F et al. Poor cell survival limits the beneficial impact of
mesenchymal stem cell transplantation on acute kidney injury. Nephron Exp Neph‐
rol 114: e107–e116, 2010.
[43] Gao et al. The use of chitosan based hydrogel for enhancing the therapeutic benefits
of adipose-derived MSCs for acute kidney injury. Biomaterials 33, 2012.
[44] Donizetti-Oliveira et al. Adipose Tissue-Derived Stem Cell Treatment Prevents Renal
Disease Progression. Cell Transplantation, Volume 21, Number 8, 1727-1741(15),
2012.
Cells and Biomaterials in Regenerative Medicine28
[45] Chen, Y.-T. Sun, C.-K. Lin Y.-C. et al., “Adipose-derived mesenchymal stem cell pro‐
tects kidneys against ischemia-reperfusion injury through suppressing oxidative
stress and inflammatory reaction,” Journal of Translational Medicine, vol. 9, article
51, 2011.
[46] Asanuma, H., Meldrum, D. R. and Meldrum, K. K. Therapeutic applications of mes‐
enchymal stem cells to repair kidney injury. J. Urol. 184, 26–33, 2010.
[47] Pino, C. J. and Humes, H. D. Stem cell technology for the treatment of acute and
chronic renal failure. Transl. Res. 156, 161–168, 2010.
[48] De Groot, K., Bahlmann, F. H., Sowa, J., Koenig, J., Menne, J., Haller, H. and Fliser, D.
Uremia causes endothelial progenitor cell deficiency. Kidney Int. 66, 641–646, 2004.
[49] Noh, H., Yu, M. R., Kim, H. J., Jeon, J. S., Kwon, S. H., Jin, S. Y., Lee, J., Jang, J., Park,
J. O., Ziyadeh, F. et al. Uremia induces functional incompetence of bone marrow-de‐
rived stromal cells. Nephrol. Dial. Transplant. 27, 218–225, 2012.
[50] Roemeling-van Rhijn, M., Reinders, M. E., de Klein, A., Douben, H., Korevaar, S. S.,
Mensah, F. K., Dor, F. J., IJzermans, J. N., Betjes, M. G., Baan, C. C. et al. Mesenchy‐
mal stem cells derived from adipose tissue are not affected by renal disease. Kidney
Int. 82, 7 48–758, 2012.
[51] Li K, Han Q, Yan X, Liao L, Zhao RC. Not a process of simple vicariousness, the dif‐
ferentiation of human adipose-derived mesenchymal stem cells to renal tubular epi‐
thelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev.
Aug;19(8):1267-75, 2010.
[52] Villanueva S, Carreño JE, Salazar L, Vergara C, Strodthoff R, Fajre F, Céspedes C,
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